Maxim initiated coverage of NeuroBo Pharmaceuticals with a Buy rating and $10 price target. The company is developing DA-1726 for obesity and DA-1241 for MASH, or metabolic dysfunction-associated steatohepatitis – spaces that have been active on the clinical, regulatory, and commercial fronts, the analyst tells investors in a research note. NeuroBo is earlier from a clinical perspective, with DA-1241 in a Phase 2a MASH study and DA-1726 in a Phase 1 obesity study, but even earlier-stage clinical trials can trigger significant rises in valuation on positive readouts, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRBO:
- NeuroBo Pharmaceuticals management to meet with Maxim Group
- NeuroBo Pharmaceuticals doses first patient in Phase 1 DA-1726 trial
- NeuroBo Pharmaceuticals files $150M mixed securities shelf
- NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
- NeuroBo Pharmaceuticals cleared to continue Phase 2a trial of DA-1241